Name: CD79A (CN 112368021 A Biosimilar) Recombinant Monoclonal Antibody
Brand: CUSABIO
SKU: CSB-RA004957MB1HU

Product Details

Uniprot No.

P11912

Target Names

CD79A

Alternative Names

B lymphocyte-specific MB1 protein antibody; B-cell antigen receptor complex-associated protein alpha chain antibody; CD 79a antibody; CD79a antibody; CD79a antigen；immunoglobulin-associated alpha antibody; CD79A antigen antibody; CD79a molecule; immunoglobulin-associated alpha antibody; CD79A_HUMAN antibody; Ig alpha antibody; Ig-alpha antibody; IGA antibody; IgM-alpha antibody; Immunoglobulin-associated alpha antibody; Ly54 antibody; MB-1 membrane glycoprotein antibody; MB1 antibody; Membrane-bound immunoglobulin-associated protein antibody; Surface IgM-associated protein antibody

Species Reactivity

Human

Immunogen

Recombinant Human CD79A protein

Immunogen Species

Homo sapiens (Human)

Conjugate

Non-conjugated

Clonality

Monoclonal

Concentration

It differs from different batches. Please contact us to confirm it.

Buffer

0.01M PBS，pH7.4

Form

Liquid

Troubleshooting and FAQs

Antibody FAQs

Storage

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Notes

Validation Status
Application-specific performance (e.g., in flow cytometry, ELISA, IHC or other assay formats) has not yet been experimentally verified by CUSABIO. Users are advised to determine the optimal working conditions empirically in their own assay systems.
Guaranteed Quality
① Antibody purity > 95% tested by SDS-PAGE.
② Endotoxin level < 0.1EU/ug tested by LAL method.

Lead Time

In stock

Description

This recombinant monoclonal antibody is a research-grade biosimilar of the CD79A-binding antibody molecules described in CN 112368021 A, targeting CD79A (also known as Igα / IGA / MB-1), a core signaling subunit of the B-cell antigen receptor (BCR) complex. CD79A forms a disulfide-linked heterodimer with CD79B (Igβ/B29) to enable BCR surface expression and transmit activation signals via its cytoplasmic ITAM motif, making it central to B-cell activation biology and BCR-dependent signaling programs.

CN 112368021 A focuses on anti-CD79A CAR molecules, describing anti-CD79A antibodies/antigen-binding fragments (e.g., scFv) as the extracellular targeting domain and proposing their use in adoptive cell-therapy concepts for CD79A-expressing cancers. This biosimilar provides the antibody component alone, enabling researchers to study CD79A target engagement, BCR-complex signaling modulation, and CD79A-directed binding/recognition characteristics in controlled experimental systems—supporting assay development and early feasibility work relevant to CD79A-targeted modalities without confounding effects from additional engineered-cell constructs or therapeutic payloads.

Usage

It is a non-therapeutic biosimilar antibody, owning the same variable region from the corresponding approved therapeutic antibody. In conclusion, it is a research-grade biosimilar antibody and expressed in mammalian cell, which can be directly used as positive controls in drug discovery or used for rapid verification of the biological functions of target protein.

Target Background

Function

Required in cooperation with CD79B for initiation of the signal transduction cascade activated by binding of antigen to the B-cell antigen receptor complex (BCR) which leads to internalization of the complex, trafficking to late endosomes and antigen presentation. Also required for BCR surface expression and for efficient differentiation of pro- and pre-B-cells. Stimulates SYK autophosphorylation and activation. Binds to BLNK, bringing BLNK into proximity with SYK and allowing SYK to phosphorylate BLNK. Also interacts with and increases activity of some Src-family tyrosine kinases. Represses BCR signaling during development of immature B-cells.

Gene References into Functions

The incidence of MYD88 and CD79B mutations in patients with CD5(+) DLBCL is lower than that in patients with DLBCL-SS, suggesting that CD5(+) DLBCL is not the same disease as DLBCL-SS in terms of gene mutation status. PMID: 27915469
Phosphorylation of CD79a causes a decrease in helical propensity in the C-terminal region, for CD79b, the opposite was observed and phosphorylation resulted in an increase of helical propensity in the C-terminal part. PMID: 24769851
High intensity of caries is associated with increased levels of some salivary components - sIgA, histatin-5 and lactoperoxidase. PMID: 24974109
CD79a plays a functional role in the tumor promoting effects of myeloid cells, and may represent a novel target for cancer therapy. PMID: 24146823
STN produced significant antitumor effects in a mouse xenograft model of CD79A/B-mutated DLBCL. PMID: 21324920
CD79a may be helpful marker in the differential diagnosis of classical Hodgkin's lymphoma and primary mediastinal B-cell lymphoma PMID: 20102401
Unlike the B29 octamer motif, the mb-1 octamer motif does not have the essential sequence required for OBF-1/Bob1 interaction, therefore its promoter is not transactivated by OBF-1/Bob1. PMID: 11907094
B cell-restricted mb-1 gene: expression, function, and lineage infidelity. Review. PMID: 12403343
There is a somatic hypermutation of this gene in B-cell lymphoma and multiple myeloma. PMID: 12651942
Results indicate that PAX5 is a more specific marker than CD79a for B-cell ALL diagnosis. PMID: 15492262
lower levels of B-cell receptor surface expression observed in chronic lymphocytic leukemia are accounted for by an impaired glycosylation and folding of the mu and CD79a chains. PMID: 15591116
FISH findings indicate that CD79a, despite its specificity for B-cell differentiation, represented the aberrant presence of a B-cell antigen in leukemias of distinct myeloid linage. PMID: 16271957
Acute leukemia with t(8;21) coexpresses CytCD79a represent biphenotypic acute leukemia. PMID: 17350472
Anti-CD79b antibodies downregulated surface B-cell receptor and were trafficked to the lysosomal-like major histocompatibility complex class II-positive compartment of a mouse xenograft model of non-Hodgkin lymphoma. PMID: 17374736
Ig-alpha was phosphorylated in all myeloma IgG BCR isolates, the 31-kD variant being phosphorylated most frequently. It was not phosphorylated in normal control B cells. PMID: 17701175
Median survival time of cytoplasmic CD79 alpha positive group was shorter than that of cytCD79a negative group in acute myeloid leukemia. PMID: 18160827

Hide All

Involvement in disease

Agammaglobulinemia 3, autosomal recessive (AGM3)

Subcellular Location

Cell membrane; Single-pass type I membrane protein.

Tissue Specificity

B-cells.

Database Links

HGNC: 1698

OMIM: 112205

KEGG: hsa:973

STRING: 9606.ENSP00000221972

UniGene: Hs.631567

Message

Product >> Product Name：
Product >> Code：
Name： *
Email： *
Company/Organization：
Phone：
Since emails may get flagged by spam filters occasionally, we recommend leaving your phone number as a precaution. Your information is safe with us.
Question/Comment： *
Your Region： *
I'd like to receive email newsletters from Cusabio

Yes

No
How do you know CUSABIO?

Email

Distributor

Search engine

Advertisement

Others
CAPTCHA verification：
Please enter the characters shown. Click the image to refresh if unclear.

Code	CSB-RA004957MB1HU
Size	US$9799
	Order now
Have Questions?	Leave a Message or Start an on-line Chat

CD79A (CN 112368021 A Biosimilar) Recombinant Monoclonal Antibody

Product Details

Related Products

Customer Reviews and Q&A

Target Background